<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>BEXSERO</title>
  <link rel="stylesheet" href="../css/end.css" />
</head>
<body>
  <div class="page">
    <!-- ====== HEADER ====== -->
    <header class="header">
      <img src="../assets/Bexsero.svg" alt="BEXSERO Logo" class="bexsero-logo" />
    </header>

    <!-- ====== REFERENCES ====== -->
    <section class="references">
      <h3>References:</h3>
      <ol>
        <li>Peate I; <i>British Journal of Nursing</i>; 1999;8(19);1290–1296.</li>
        <li>Presa J; <i>Infect Dis Ther</i>; 2019;8:307–333.</li>
        <li>Kellman J; <i>Nurs Clin N Am</i>; 2019;54:227–243.</li>
        <li>Thompson MJ; <i>Lancet</i>; 2006;367:397–403.</li>
        <li>Bianchi A; <i>Journal of Preventive Medicine and Hygiene</i>; 2015;56;E140–E143.</li>
      </ol>
    </section>

    <!-- ====== SAFETY INFO ====== -->
    <section class="safety">
      <h3>Safety information of Bexsero:</h3>
      <p><strong>Contraindications:</strong><br>
      Hypersensitivity to the active substances or to any of the excipients.</p>
      <p><strong>Undesirable effects:</strong></p>
      <p>Infants and children (up to 10 years of age):<br>
      Very common: eating disorders, sleepiness, unusual crying, headache, diarrhoea, vomiting (uncommon after booster), rash (children aged 12 to 23 months) (uncommon after booster), arthralgia, fever (≥38°C), injection site tenderness (including severe injection site tenderness defined as crying when injected limb is moved), injection site erythema, injection site swelling, injection site induration, irritability.
      </p>
      <p>Common: rash (infants and children 2 to 10 years of age).</p>
      <p>Adolescents (from 11 years of age) and adults:<br>
      Very common: headache, nausea, myalgia, arthralgia, injection site pain (including severe injection site pain defined as unable to perform normal daily activity), injection site swelling, injection site induration, injection site erythema.</p>
    </section>

    <!-- ====== FOOTER ====== -->
    <footer class="footer">
      <div class="footer-left">
        <img src="../assets/gsk.png" alt="GSK Logo" class="gsk-logo" />
        <p>
          PM-SA-BEX-WCNT-250002 | August 2025<br />
          For full prescribing information, please refer to the data sheet or contact GlaxoSmithKline, P.O. Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia.
          Telephone: +966 12 653 6566 or via <a href="mailto:gcc.medinfo@gsk.com">gcc.medinfo@gsk.com</a><br />
          To report Adverse Events, please contact via <a href="mailto:sau.safety@gsk.com">sau.safety@gsk.com</a><br />
          To report Quality related product complaints, please contact via <a href="mailto:ksa.productqualitycomplaint@gsk.com">ksa.productqualitycomplaint@gsk.com</a><br /><br />
          ©2025 GSK group of companies or its licensor.<br />
          Trademarks are owned by or licensed to the GSK group of companies.
        </p>
      </div>

      <div class="footer-right">
        <img src="../assets/QR_code.svg" alt="QR Code" class="qr-code" />
      </div>
    </footer>

    <!-- ====== RESTART BUTTON ====== -->
    <button class="restart-btn" onclick="window.location.href='index.html'">Restart</button>
  </div>
</body>
</html>
